AXSM
Axsome Therapeutics, Inc.
Nasdaq: AXSM · New York, NY · Healthcare
$182.97-5.72 (-3.03%)Closed
Market Cap$9.31B
Cash$322.9Mmost recent
Runway22 mo$43.4M Q burn
P/E (TTM)—EPS $-3.68
52-Wk Range$100.39 – $189.10
Avg Volume607.9K3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$182.97+157.3%
Pipeline

Drug candidates sponsored by Axsome Therapeutics · ClinicalTrials.gov

16 drugs · 32 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Solriamfetol
Excessive Daytime Sleepiness+2 more
Completed
2022-09-19past
1
Phase 4AXS-05
Major Depressive Disorder+7 more
Recruiting
2026-03past
9
Phase 3AXS-02 (oral zoledronate)
Complex Regional Pain Syndrome+1 more
Unknown
2019-01past
1
Phase 3AXS-07 (MoSEIC meloxicam and rizatriptan)
Migraine
Completed
2020-03-16past
2
Phase 3AXS-07
Migraine
Completed
2020-09-22past
1
Phase 3AXS-05 (dextromethorphan and bupropion) oral tablets
Major Depressive Disorder+2 more
Completed
2020-10-23past
1
Phase 3AXS-02
Osteoarthritis, Knee
Unknown
2020-12past
1
Phase 3AXS-12 (reboxetine)
Narcolepsy+4 more
Completed
2024-11-15past
3
Phase 3AXS-07 (meloxicam-rizatriptan)
Migraine
Completed
2024-11-27past
1
Phase 3Solriamfetol 300 mg
Major Depressive Disorder
Completed
2024-12-31past
1
Phase 3AXS-05 (dextromethorphan-bupropion)
Agitation in Patients With Dementia of the Alzheimer's Type+4 more
Completed
2025-02-17past
3
Phase 3Solriamfetol 150 mg
ADHD+4 more
Recruiting
2026-12
4
Phase 3Solriamfetol 75mg, 150 mg, or 300 mg
Binge-Eating Disorder
Enrolling
2026-12
1
Phase 3AXS-14 (Esreboxetine)
Fibromyalgia
Recruiting
2028-03
1
Phase 1Solriamfetol 150 mg Oral Tablet
Narcolepsy+4 more
Completed
2022-04-15past
1
N/ASunosi (solriamfetol)
Narcolepsy+2 more
Recruiting
2029-09
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for AXSM. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.